Literature DB >> 9570492

Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity.

M Maes1, R Verkerk, E Vandoolaeghe, A Lin, S Scharpé.   

Abstract

Previous research has revealed that major depression is accompanied by disorders in excitatory amino acids, e.g. glutamate and aspartate, and alterations in serum levels of other amino acids, e.g. serine, glycine and taurine. The aim of the present study was to examine serum levels of aspartate, asparagine, glutamate, glutamine, serine, glycine, threonine, histidine, alanine, taurine and arginine in major depression patients with treatment-resistant depression (TRD). No significant differences in the serum concentrations of any of the above amino acids could be found between patients with and without TRD and normal controls. Non-responders to treatment with antidepressants during a period of 5 weeks were characterized by significantly lower serum levels of aspartate, asparagine, serine, threonine and taurine. A 5-week period of treatment with antidepressants significantly reduced the serum levels of aspartate, glutamate and taurine, and significantly increased the serum concentrations of glutamine. The results suggest that alterations in serum levels of aspartate, asparagine, serine, threonine and taurine may predict the subsequent response to treatment with antidepressants, and that the latter may modulate serum levels of excitatory amino acids and taurine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9570492     DOI: 10.1111/j.1600-0447.1998.tb10004.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  45 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 2.  Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

Authors:  Cagri Yüksel; Dost Öngür
Journal:  Biol Psychiatry       Date:  2010-08-21       Impact factor: 13.382

Review 3.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

4.  Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study.

Authors:  Tomislav Kovačević; Ivan Skelin; Luciano Minuzzi; Pedro Rosa-Neto; Mirko Diksic
Journal:  Brain Res Bull       Date:  2012-01-31       Impact factor: 4.077

Review 5.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

6.  Metabolomic differences in heart failure patients with and without major depression.

Authors:  David C Steffens; K Ranga R Krishnan; Edward D Karoly; Matthew W Mitchell; Christopher M O'Connor; Rima Kaddurah-Daouk
Journal:  J Geriatr Psychiatry Neurol       Date:  2010-01-25       Impact factor: 2.680

7.  Atorvastatin and Fluoxetine Prevent Oxidative Stress and Mitochondrial Dysfunction Evoked by Glutamate Toxicity in Hippocampal Slices.

Authors:  Fabiana K Ludka; Tharine Dal-Cim; Luisa Bandeira Binder; Leandra Celso Constantino; Caio Massari; Carla I Tasca
Journal:  Mol Neurobiol       Date:  2016-04-06       Impact factor: 5.590

Review 8.  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors:  Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

Review 9.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

10.  Possible Role of Platelet GluR1 Receptors in Comorbid Depression and Cardiovascular Disease.

Authors:  Hu Chen
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.